Taivex announced that its Phase I clinical trial drugs, T-1101 and T-1201, have been invited to present their project progress at the Korean Society of Medical Oncology (KSMO) 2024 Annual Meeting. The company will unveil the unique properties of these innovative therapies and their clinical trial designs, highlighting their potential impact on cancer treatment.

The KSMO Annual Meeting brings together global experts and scholars, serving as a premier platform for sharing breakthroughs and fostering collaboration in oncology. This year’s theme, “From Insights to Impact: Defeating Cancer Together,” underscores the importance of interdisciplinary and international efforts in advancing cancer therapies.

T-1101 is the first-in-class oral small-molecule inhibitor targeting Hec1/Nek2, developed for the treatment of advanced, refractory solid tumors.

T-1201 is a novel SN38-conjugated targeted small-molecule anti-cancer drug, designed to address unmet needs in patients with advanced, refractory solid tumors.

Taivex expressed that being part of KSMO 2024 is a significant recognition of its efforts in innovative drug development. The company views this as an opportunity to showcase its progress and engage with global experts, reaffirming its commitment to advancing cancer therapies and offering new hope to patients worldwide.